Literature DB >> 9781930

ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients.

R Fogari1, A Zoppi, P Lazzari, P Preti, A Mugellini, L Corradi, P Lusardi.   

Abstract

The aim of this study was to compare the effects of the angiotensin-converting enzyme (ACE) inhibitor perindopril and the angiotensin II antagonist losartan on insulin sensitivity and plasma fibrinogen in overweight hypertensive patients. Twenty-eight overweight mild to moderate [diastolic blood pressure (DBP) >90 and <110 mm Hg] hypertensives aged 43-64 years, after a 4-week placebo period, were randomized to perindopril, 4 mg o.d., or losartan, 50 mg o.d., for 6 weeks. Then, after a new placebo period, patients were crossed to the alternative regimen for further 6 weeks. At the end of the placebo and of the treatment periods, blood pressure was measured, plasma fibrinogen was evaluated, and insulin sensitivity was assessed by the euglycemic, hyperinsulinemic clamp technique. Glucose infusion rate (GIR) during the last 30 min of clamp and total glucose requirement (TGR) were evaluated. Both perindopril and losartan reduced SBP (by a mean of 20.2 mm Hg, p < 0.001 vs. placebo; and 15.8 mm Hg, p = 0.002 vs. placebo, respectively) and DBP (by a mean of 15.2 mm Hg, p = 0.001 vs. placebo, and 11.8 mm Hg, p = 0.01 vs. placebo respectively), with no difference between the two treatments. GIR was significantly increased by perindopril (+2.91 mg/min/kg, p = 0.042 vs. placebo), but not by losartan (+0.28 mg/min/kg, NS). TGR was not modified by losartan but was increased by perindopril (+9.3 g, p = 0.042 vs. placebo). Plasma fibrinogen levels were reduced by perindopril (-53.4 mg/dl, p = 0.022 vs. placebo) but not by losartan (-16.8 mg/dl, NS). The perindopril-induced decrease in fibrinogen was correlated with the increase in GIR (r = 0.39; p < 0.01). These findings suggest that fibrinogen decrease produced by the ACE inhibitor is related to its action on insulin sensitivity, which seems to be dependent not on angiotensin II blockade but rather on other mechanisms.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9781930     DOI: 10.1097/00005344-199810000-00014

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  22 in total

Review 1.  Antihypertensive medications and blood sugar: theories and implications.

Authors:  David F Blackburn; Thomas W Wilson
Journal:  Can J Cardiol       Date:  2006-03-01       Impact factor: 5.223

2.  The effects of nebivolol on fibrinolytic parameters in mild and moderate hypertensive patients.

Authors:  Bahman Tarighi; Turhan Kurum; Muzaffer Demir; Sen Nur Azcan
Journal:  Can J Cardiol       Date:  2007-06       Impact factor: 5.223

3.  Effects of losartan on whole body, skeletal muscle and vascular insulin responses in obesity/insulin resistance without hypertension.

Authors:  A A Lteif; R L Chisholm; K Gilbert; R V Considine; K J Mather
Journal:  Diabetes Obes Metab       Date:  2011-11-24       Impact factor: 6.577

4.  Effect of angiotensin receptor blockade on insulin sensitivity and endothelial function in abdominally obese hypertensive patients with impaired fasting glucose.

Authors:  Todd S Perlstein; Robert R Henry; Kieren J Mather; Michael R Rickels; Nicola I Abate; Scott M Grundy; Yabing Mai; Jeanine B Albu; Jennifer B Marks; James L Pool; Mark A Creager
Journal:  Clin Sci (Lond)       Date:  2012-02       Impact factor: 6.124

Review 5.  The use of ACE inhibitors on diabetic patients without renal disease.

Authors:  Dmitri Kirpichnikov; Nathaniel Winer; James R Sowers
Journal:  Curr Diab Rep       Date:  2002-02       Impact factor: 4.810

Review 6.  The choice of antihypertensive drugs in patients with diabetes: angiotensin II and beyond.

Authors:  Kambiz Kalantarinia; Helmy M Siragy
Journal:  Curr Diab Rep       Date:  2002-10       Impact factor: 4.810

Review 7.  Role of ACE inhibitors in treating hypertensive diabetic patients.

Authors:  Dmitri Kirpichnikov; James R Sowers
Journal:  Curr Diab Rep       Date:  2002-06       Impact factor: 4.810

8.  Effect of benazepril amlodipine combination on fibrinolysis in hypertensive diabetic patients.

Authors:  Roberto Fogari; Paola Preti; Pierangelo Lazzari; Luca Corradi; Annalisa Zoppi; Elena Fogari; Amedeo Mugellini
Journal:  Eur J Clin Pharmacol       Date:  2003-06-27       Impact factor: 2.953

9.  Cardiovascular and autonomic phenotype of db/db diabetic mice.

Authors:  Danielle Senador; Keerthy Kanakamedala; Maria Claudia Irigoyen; Mariana Morris; Khalid M Elased
Journal:  Exp Physiol       Date:  2009-02-13       Impact factor: 2.969

10.  Effects of dietary protein restriction on albumin and fibrinogen synthesis in macroalbuminuric type 2 diabetic patients.

Authors:  M Giordano; P Lucidi; T Ciarambino; L Gesuè; P Castellino; M Cioffi; P Gresele; G Paolisso; P De Feo
Journal:  Diabetologia       Date:  2007-11-17       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.